title: Edoxaban in patients with atrial fibrillation.
abstract: Edoxaban, a direct factor Xa inhibitor, was extensively studied in the prevention and treatment of venous thromboembolism and in patients with nonvalvular atrial fibrillation (AF). The aim of this review is to focus specifically on the efficacy and safety profile of edoxaban in patients with AF from preclinical development through the phase III trial that led to regulatory approval.
authors.affiliation: Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
authors.forename: Alon
authors.initials: A
authors.lastname: Eisen
authors.affiliation: Brigham and Women's Hospital and Harvard Medical School Boston, TIMI Study Group, 350 Longwood Avenue, 1st Floor Offices, Boston, MA 02115, USA.
authors.forename: Christian T
authors.initials: CT
authors.lastname: Ruff
mesh_terms: D000284:Administration, Oral; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy; D065427:Factor Xa Inhibitors; D006801:Humans; D011725:Pyridines / Q000008:administration & dosage*; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013844:Thiazoles / Q000008:administration & dosage*
chemical_list: D065427:Factor Xa Inhibitors; D011725:Pyridines; D013844:Thiazoles; C552171:edoxaban
keywords: Novel oral anticoagulants; atrial fibrillation; edoxaban; factor xa inhibitor; non-vitamin K oral anticoagulants